<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995212</url>
  </required_header>
  <id_info>
    <org_study_id>CR845-210401</org_study_id>
    <nct_id>NCT03995212</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cara Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cara Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the&#xD;
      safety and efficacy of twice-daily (BID) oral CR845 1.0 mg in patients with PBC with&#xD;
      moderate-to-severe pruritus. The study includes a 16-week Treatment Period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of a Screening Visit, a 7-day Run-in Period, a 16-week Treatment&#xD;
      Period, and a Follow-up Visit (approximately 7-10 days after the last dose of study drug).&#xD;
      Informed consent will be obtained prior to performing any study-specific procedures.&#xD;
&#xD;
      The Screening Visit will occur within 7 to 28 days prior to randomization to assess&#xD;
      eligibility.&#xD;
&#xD;
      Day 1 of the Treatment Period will be defined as the day of the administration of the first&#xD;
      dose of study drug. If patients continue to meet all inclusion and no exclusion criteria at&#xD;
      the end of the 7-day Run-in Period, they will be randomized in a 1:1 ratio to receive either&#xD;
      placebo or CR845 tablets at a dose of 1.0 mg orally BID for 16 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 16 with respect to the weekly mean of the daily 24-hour Worst Itching Intensity Numeric Rating Scale (WI-NRS) score.</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where &quot;0&quot; represents &quot;no itching&quot; and &quot;10&quot; represents &quot;worst itching imaginable&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in itch-related quality of life as assessed by the change from baseline to Week 16 in total Skindex-10 Scale score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Skindex-10 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: disease, mood/emotional distress, and social functioning domain. A lower total score represents better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in itch-related quality of life as assessed by the change from baseline to Week 16 in 5-D Itch Scale score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The 5-D Itch Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past 2 weeks. The questions cover five dimensions of itch including the degree, duration of itch/day, direction (improvement/worsening), disability (impact on activities such as work), and body distribution of itch. A lower total score represents better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of itch intensity as assessed by the proportion of patients achieving an improvement from baseline ≥3 points with respect to the weekly mean of the daily 24-hour WI-NRS score at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where &quot;0&quot; represents &quot;no itching&quot; and &quot;10&quot; represents &quot;worst itching imaginable&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholestatic Pruritus</condition>
  <arm_group>
    <arm_group_label>CR845 1.0 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral CR845 1.0 mg tablet administered twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo tablet administered twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CR845 1.0 mg</intervention_name>
    <description>Oral CR845 1.0 mg administered twice daily</description>
    <arm_group_label>CR845 1.0 mg</arm_group_label>
    <other_name>CR845</other_name>
    <other_name>Difelikefalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Placebo administered twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        To be eligible for inclusion into the study, a patient must meet the following criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of PBC;&#xD;
&#xD;
          -  If currently taking ursodeoxycholic acid (UDCA), should be on stable dose for &gt;12&#xD;
             weeks prior to screening and plan on continuing to take UDCA throughout the study;&#xD;
&#xD;
          -  If previously taking UDCA, should have discontinued its use &gt;12 weeks prior to&#xD;
             screening;&#xD;
&#xD;
          -  Self-reports experiencing daily or near-daily pruritus during the month prior to&#xD;
             screening;&#xD;
&#xD;
          -  Prior to randomization has a mean baseline WI-NRS score indicative of moderate to&#xD;
             severe pruritus.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        A patient will be excluded from the study if any of the following criteria are met:&#xD;
&#xD;
          -  Presence of Child-Pugh Class C decompensated cirrhosis at screening;&#xD;
&#xD;
          -  Itching secondary to biliary obstruction;&#xD;
&#xD;
          -  History or presence of hepatocellular carcinoma, hepatic abscess, or acute portal vein&#xD;
             thrombosis;&#xD;
&#xD;
          -  Current placement on liver transplantation list with anticipated liver transplant&#xD;
             during the course of the study or current Model for End-stage Liver Disease (MELD)&#xD;
             score ≥15;&#xD;
&#xD;
          -  Alanine aminotransferase or aspartate aminotransferase &gt;5 × upper limit of normal at&#xD;
             screening, or within 2 months prior to screening;&#xD;
&#xD;
          -  Anticipates receiving an opioid antagonist (eg, naloxone, naltrexone) or opioid-mixed&#xD;
             agonist-antagonist (eg, buprenorphine, nalbuphine) from the start of screening through&#xD;
             the end of the Treatment Period;&#xD;
&#xD;
          -  New or change of treatment with antihistamines and corticosteroids (oral, intravenous,&#xD;
             or topical), opioids, gabapentin, pregabalin, cholestyramine, rifampicin or fibrates&#xD;
             within 14 days prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique Menzaghi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cara Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgine Ragsdale, PharmD</last_name>
    <phone>203-406-3700</phone>
    <email>clinicaltrials.gov@caratherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site 2</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 19, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Biliary Cholangitis</keyword>
  <keyword>Pruritus</keyword>
  <keyword>CR845</keyword>
  <keyword>Chronic Itch</keyword>
  <keyword>difelikefalin</keyword>
  <keyword>Itch</keyword>
  <keyword>Itching</keyword>
  <keyword>Generalized pruritus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

